Amoeba SA stock analysis
Amoeba SA (0RAE) Share Price & Analysis
0RAE Stock Chart & Stats
- Day’s Range
- EUR 0.30 - EUR 0.30
- 52-Week Range
- EUR 0.25 - EUR 1.12
- Previous Close
- EUR 0.31
- Volume
- N/A
- Average Volume (3M)
- 5,668
- Market Cap
- EUR 36.23M
- Enterprise Value
- EUR 78.49M
- Total Cash (Recent Filing)
- EUR 5.52M
- Total Debt (Recent Filing)
- EUR 12.67M
- Price to Earnings (P/E)
- ―
- Beta
- 1.59
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Biological Platform
A proprietary biological platform gives Amoéba a differentiated basis for developing products in markets seeking lower-impact microbial control and bio-based performance. If regulatory and commercial execution progress, the platform may support multiple products and create longer-term intellectual-property-led growth opportunities.
Multiple Application Markets
Exposure to both agricultural inputs and industrial applications broadens the potential addressable market beyond a single product category. This application diversity can provide strategic flexibility, allowing the company to prioritize the regulatory or commercial pathway with the strongest adoption potential over the coming quarters.
Some Improvement In Losses And Cash Flow
Although performance remains weak, the reported narrowing of losses versus 2023 and improvement in free cash flow versus 2024 indicate some movement away from the worst historical levels. Sustaining that direction could gradually improve funding needs and provide a more credible basis for future operating leverage.
Bears Say
Revenue Collapse
Revenue falling to zero demonstrates that the company has not yet established dependable commercial scale. Without recurring sales, fixed research, regulatory and operating costs remain difficult to absorb, limiting visibility into future margins and making the business highly dependent on successful product commercialization.
Persistent Unprofitable Operations
Repeated operating and net losses show that the current business model has not reached sustainable profitability. Continued negative earnings can consume available resources, restrict reinvestment choices, and leave future value creation dependent on achieving meaningful revenue growth and improved gross economics.
Negative Equity And Rising Debt
Negative equity combined with materially higher debt weakens financial resilience and reduces flexibility to fund development internally. The balance-sheet deterioration increases reliance on refinancing or new funding, while declining assets and leverage make execution setbacks more consequential for shareholders and creditors.
Amoeba SA News
0RAE FAQ
What was Amoeba SA’s price range in the past 12 months?
What is Amoeba SA’s market cap?
When is Amoeba SA’s upcoming earnings report date?
How were Amoeba SA’s earnings last quarter?
Is Amoeba SA overvalued?
Does Amoeba SA pay dividends?
What is Amoeba SA’s EPS estimate?
How many shares outstanding does Amoeba SA have?
What happened to Amoeba SA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Amoeba SA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Amoeba SA
Amoéba S.A. focuses on the development and commercialization of anti-microbial and anti-fungal products. The company's primary innovation centers on harnessing the unique properties of the Willaertia magna C2c Maky amoeba, which it is applying across various fields. These applications are designed to mitigate biological risks in critical areas like water purification, the treatment of human injuries, and safeguarding agricultural crops. Established in 2010, Amoéba S.A. is based in Chassieu, France.
- Sector
- Healthcare
- Industry
- Agricultural Inputs
- CEO
- Jean-Francois Doucet
- Employees
- 23
- Website
- amoeba-nature.com
- Address
- 38 Avenue de FrEres Montgolfier, Chassieu, AR, 69680, FR
Amoeba SA (0RAE) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 4 | 11 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 4 | 0 | 8 |








